Aurinia (AUPH) CEO Greenleaf has 100,171 shares withheld for RSU taxes

Rhea-AI Filing Summary

Aurinia Pharmaceuticals Inc. Chief Executive Officer Peter Greenleaf reported a Form 4 transaction involving company common stock. On February 20, 2026, 100,171 shares were disposed of at $14.40 per share in a tax-withholding disposition, meaning shares were withheld to cover tax obligations upon vesting of restricted stock units rather than sold in an open-market trade. After this transaction, Greenleaf directly owned 1,744,866 common shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Greenleaf Peter

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	100,171	$14.40	$1.44M

Holdings After Transaction: Common Stock — 1,744,866 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Greenleaf Peter

(Last) (First) (Middle)

#140, 14315-118 AVENUE

(Street)

EDMONTON A0 T5L 4S6

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aurinia Pharmaceuticals Inc. [ AUPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/20/2026		F		100,171(1)	D	$14.4	1,744,866	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units.

Remarks:

	/s/ Peter S. Greenleaf	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Aurinia Pharmaceuticals (AUPH) CEO Peter Greenleaf report?

Peter Greenleaf reported a tax-related share disposition of Aurinia Pharmaceuticals common stock. On February 20, 2026, 100,171 shares were withheld to satisfy tax obligations upon vesting of restricted stock units, rather than being sold in a discretionary open-market transaction.

How many Aurinia Pharmaceuticals (AUPH) shares were involved in Peter Greenleaf’s Form 4 filing?

The Form 4 shows 100,171 Aurinia Pharmaceuticals common shares were disposed of. These shares were withheld by the company to cover tax withholding obligations tied to vesting restricted stock units, instead of being sold by Greenleaf on the open market for cash proceeds.

Was Peter Greenleaf’s Aurinia (AUPH) Form 4 transaction an open-market sale?

No, the transaction was not an open-market sale. It was a tax-withholding disposition in which 100,171 vested RSU shares were withheld to satisfy tax obligations, as described in the footnote, rather than voluntarily sold into the market for investment or liquidity purposes.

What price per share is reported in Peter Greenleaf’s Aurinia (AUPH) Form 4 transaction?

The Form 4 reports a price of $14.40 per Aurinia common share for the tax-withholding disposition. This price is used to calculate the value of 100,171 shares withheld to cover tax obligations when restricted stock units vested for the Chief Executive Officer.

How many Aurinia Pharmaceuticals (AUPH) shares does Peter Greenleaf hold after this Form 4 event?

After the tax-withholding disposition, Peter Greenleaf directly holds 1,744,866 Aurinia Pharmaceuticals common shares. This post-transaction holding reflects his remaining ownership following the withholding of 100,171 shares to satisfy tax obligations on vested restricted stock units.

What does the footnote in Aurinia (AUPH) CEO Peter Greenleaf’s Form 4 explain?

The footnote explains that the reported 100,171 shares represent stock withheld to satisfy tax withholding obligations when restricted stock units vested. It clarifies the transaction is a tax-withholding disposition, not a discretionary sale of Aurinia Pharmaceuticals shares by the Chief Executive Officer.